Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers? A population-based study

NICE guidance recommends the use of paclitaxel and a platinum therapy for all cases of ovarian cancer. We report our experience of treating 133 patients with ovarian cancer over a 3-year period. Where indicated, 91% received chemotherapy. A taxane/platinum combination was found to be appropriate in...

Descripción completa

Detalles Bibliográficos
Autores principales: McNally, O M, Delaney, E, Petty, R D, Cruickshank, M E, Hutcheon, A W, Parkin, D E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376968/
https://www.ncbi.nlm.nih.gov/pubmed/12966409
http://dx.doi.org/10.1038/sj.bjc.6601071
_version_ 1782154762697834496
author McNally, O M
Delaney, E
Petty, R D
Cruickshank, M E
Hutcheon, A W
Parkin, D E
author_facet McNally, O M
Delaney, E
Petty, R D
Cruickshank, M E
Hutcheon, A W
Parkin, D E
author_sort McNally, O M
collection PubMed
description NICE guidance recommends the use of paclitaxel and a platinum therapy for all cases of ovarian cancer. We report our experience of treating 133 patients with ovarian cancer over a 3-year period. Where indicated, 91% received chemotherapy. A taxane/platinum combination was found to be appropriate in 63% of patients only.
format Text
id pubmed-2376968
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23769682009-09-10 Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers? A population-based study McNally, O M Delaney, E Petty, R D Cruickshank, M E Hutcheon, A W Parkin, D E Br J Cancer Clinical NICE guidance recommends the use of paclitaxel and a platinum therapy for all cases of ovarian cancer. We report our experience of treating 133 patients with ovarian cancer over a 3-year period. Where indicated, 91% received chemotherapy. A taxane/platinum combination was found to be appropriate in 63% of patients only. Nature Publishing Group 2003-09-15 2003-09-09 /pmc/articles/PMC2376968/ /pubmed/12966409 http://dx.doi.org/10.1038/sj.bjc.6601071 Text en Copyright © 2003 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical
McNally, O M
Delaney, E
Petty, R D
Cruickshank, M E
Hutcheon, A W
Parkin, D E
Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers? A population-based study
title Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers? A population-based study
title_full Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers? A population-based study
title_fullStr Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers? A population-based study
title_full_unstemmed Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers? A population-based study
title_short Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers? A population-based study
title_sort is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers? a population-based study
topic Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376968/
https://www.ncbi.nlm.nih.gov/pubmed/12966409
http://dx.doi.org/10.1038/sj.bjc.6601071
work_keys_str_mv AT mcnallyom isoptimalfirstlinechemotherapydeliverableinallnewlydiagnosedovariancancersapopulationbasedstudy
AT delaneye isoptimalfirstlinechemotherapydeliverableinallnewlydiagnosedovariancancersapopulationbasedstudy
AT pettyrd isoptimalfirstlinechemotherapydeliverableinallnewlydiagnosedovariancancersapopulationbasedstudy
AT cruickshankme isoptimalfirstlinechemotherapydeliverableinallnewlydiagnosedovariancancersapopulationbasedstudy
AT hutcheonaw isoptimalfirstlinechemotherapydeliverableinallnewlydiagnosedovariancancersapopulationbasedstudy
AT parkinde isoptimalfirstlinechemotherapydeliverableinallnewlydiagnosedovariancancersapopulationbasedstudy

Ejemplares similares